Quote:
Originally Posted by Trapper John
Doc, I am helping a friend who is in the process of acquiring a nano-technology that can be applied to antibiotic formulations. The idea is to enhance bioavailability (lower dosages) in PO formulations. Also reduce adverse event occurrence (reduced toxicity). The initial target market will be military applications.
The preliminary data is very encouraging.
If you were to select any of the existing antibiotics (older ones too) that could be re-purposed, what would those be and why?
Any of you active 18Ds please chime in too.
Thanks,
JDT
Sine Pari
|
I'd go with vancomycin or daptomycin. Right now linezolid is really the only oral drug for treatment of serious MRSA infections, and the treatment for things like endocarditis often goes on for weeks. Having a couple of more PO options would save a lot of time, effort, and money.
Ceftriaxone would be another option due to its frequent use in pneumonia as well as gonorrhea.
For military applications, I'd consider imipenem. If the technology improves absorption and bioavailability in shock states, this could be useful in the prolonged care setting. A limiting factor on oral moxifloxacin absorption in that environment is poor perfusion of the gut in a seriously injured trauma patient.
j.r.